-
Je něco špatně v tomto záznamu ?
Tacrolimus versus cyclosporine a combined with post-transplantation cyclophosphamide for AML In first complete remission: a study from the acute leukemia working party (EBMT)
G. Bug, M. Labopin, A. Kulagin, D. Blaise, AM. Raiola, J. Vydra, S. Sica, M. Kwon, L. López-Corral, S. Bramanti, P. von dem Borne, M. Itälä-Remes, M. Martino, Y. Koc, E. Brissot, S. Giebel, A. Nagler, F. Ciceri, M. Mohty
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, srovnávací studie, multicentrická studie
NLK
Free Medical Journals
od 1997 do Před 1 rokem
Freely Accessible Science Journals
od 1997 do Před 1 rokem
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- akutní myeloidní leukemie * terapie mortalita MeSH
- cyklofosfamid * terapeutické užití MeSH
- cyklosporin * terapeutické užití MeSH
- dítě MeSH
- dospělí MeSH
- imunosupresiva terapeutické užití MeSH
- indukce remise MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- nemoc štěpu proti hostiteli * prevence a kontrola mortalita etiologie MeSH
- předškolní dítě MeSH
- retrospektivní studie MeSH
- senioři MeSH
- takrolimus * terapeutické užití MeSH
- transplantace hematopoetických kmenových buněk * metody MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- srovnávací studie MeSH
Choice of calcineurin inhibitor may impact the outcome of patients undergoing T-cell replete hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PT-Cy) and mycophenolate mofetil (MMF) for prophylaxis of graft-versus-host disease (GVHD). We retrospectively analyzed 2427 patients with acute myeloid leukemia (AML) in first remission transplanted from a haploidentical (n = 1844) or unrelated donor (UD, n = 583) using cyclosporine A (CSA, 63%) or tacrolimus (TAC, 37%) and PT-Cy/MMF. In univariate analysis, CSA and TAC groups did not differ in 2-year leukemia-free or overall survival, cumulative incidence (CI) of relapse or non-relapse mortality. CI of severe grade III-IV acute GVHD was lower with TAC (6.6% vs. 9.1%, p = 0.02), without difference in grade II-IV acute GVHD or grade III-IV acute GVHD/severe chronic GVHD, relapse-free survival (GRFS). In multivariate analysis, TAC was associated with a lower risk of severe grade III-IV acute GVHD solely with haploidentical donors (HR 0.64 [95% CI, 0.42-0.98], p = 0.04), but not UD (HR 0.49 [95% CI, 0.2-1.21], p = 0.12). There was no significant difference for chronic GVHD. In conclusion, PT-Cy/MMF-based GVHD prophylaxis resulted in favorable OS and GRFS, irrespective of the CNI added. In haploidentical HCT, TAC seemed to prevent severe acute GVHD more effectively than CSA without impact on other outcome parameters.
Chaim Sheba Medical Center Tel Hashomer Israel
Goethe University Frankfurt University Hospital Dept of Medicine 2 Frankfurt am Main Germany
Hospital Universitario de Salamanca Salamanca Spain
Institute of Hematology and Blood Transfusion Prague Czech Republic
IRCCS San Martino Hospital Genova Italy
IRCCS San Raffaele Scientific Institute Milan Italy
Leiden University Medical Center Leiden Netherlands
Maria Sklodowska Curie National Research Institute of Oncology Gliwice Branch Gliwice Poland
Medicana International Hospital Istanbul Turkey
RM Gorbacheva Research Institute Pavlov University St Petersburg Russian Federation
Sorbonne University Department of Hematology Saint Antoine Hospital INSERM UMR 938 Paris France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25004060
- 003
- CZ-PrNML
- 005
- 20250206105110.0
- 007
- ta
- 008
- 250121s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41409-024-02331-1 $2 doi
- 035 __
- $a (PubMed)38961258
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Bug, Gesine $u Goethe University Frankfurt, University Hospital, Dept of Medicine 2, Frankfurt am Main, Germany. g.bug@em.uni-frankfurt.de $1 https://orcid.org/000000032359131X
- 245 10
- $a Tacrolimus versus cyclosporine a combined with post-transplantation cyclophosphamide for AML In first complete remission: a study from the acute leukemia working party (EBMT) / $c G. Bug, M. Labopin, A. Kulagin, D. Blaise, AM. Raiola, J. Vydra, S. Sica, M. Kwon, L. López-Corral, S. Bramanti, P. von dem Borne, M. Itälä-Remes, M. Martino, Y. Koc, E. Brissot, S. Giebel, A. Nagler, F. Ciceri, M. Mohty
- 520 9_
- $a Choice of calcineurin inhibitor may impact the outcome of patients undergoing T-cell replete hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PT-Cy) and mycophenolate mofetil (MMF) for prophylaxis of graft-versus-host disease (GVHD). We retrospectively analyzed 2427 patients with acute myeloid leukemia (AML) in first remission transplanted from a haploidentical (n = 1844) or unrelated donor (UD, n = 583) using cyclosporine A (CSA, 63%) or tacrolimus (TAC, 37%) and PT-Cy/MMF. In univariate analysis, CSA and TAC groups did not differ in 2-year leukemia-free or overall survival, cumulative incidence (CI) of relapse or non-relapse mortality. CI of severe grade III-IV acute GVHD was lower with TAC (6.6% vs. 9.1%, p = 0.02), without difference in grade II-IV acute GVHD or grade III-IV acute GVHD/severe chronic GVHD, relapse-free survival (GRFS). In multivariate analysis, TAC was associated with a lower risk of severe grade III-IV acute GVHD solely with haploidentical donors (HR 0.64 [95% CI, 0.42-0.98], p = 0.04), but not UD (HR 0.49 [95% CI, 0.2-1.21], p = 0.12). There was no significant difference for chronic GVHD. In conclusion, PT-Cy/MMF-based GVHD prophylaxis resulted in favorable OS and GRFS, irrespective of the CNI added. In haploidentical HCT, TAC seemed to prevent severe acute GVHD more effectively than CSA without impact on other outcome parameters.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a takrolimus $x terapeutické užití $7 D016559
- 650 12
- $a cyklofosfamid $x terapeutické užití $7 D003520
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a cyklosporin $x terapeutické užití $7 D016572
- 650 12
- $a akutní myeloidní leukemie $x terapie $x mortalita $7 D015470
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a transplantace hematopoetických kmenových buněk $x metody $7 D018380
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a nemoc štěpu proti hostiteli $x prevence a kontrola $x mortalita $x etiologie $7 D006086
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Labopin, Myriam $u Sorbonne University, Department of Hematology, Saint Antoine Hospital, INSERM UMR 938, Paris, France $1 https://orcid.org/0000000345144748
- 700 1_
- $a Kulagin, Alexander $u RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian Federation $1 https://orcid.org/0000000295894136
- 700 1_
- $a Blaise, Didier $u Transplant and cellular immunotherapy program, Department of hematology, Institut Paoli Calmettes, Management Sport Cancer lab, Luminy, Aix Marseille University, Marseille, France $1 https://orcid.org/0000000256849447
- 700 1_
- $a Raiola, Anna Maria $u IRCCS San Martino Hospital, Genova, Italy
- 700 1_
- $a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/0000000242743895
- 700 1_
- $a Sica, Simona $u Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica Sacro Cuore, Rome, Italy $1 https://orcid.org/0000000324263465
- 700 1_
- $a Kwon, Mi $u Department of Hematology, Hospital General Universitario Gregorio Marañon, Instituto de Investigación Sanitaria Gregorio Marañón, Univesidad Complutense de Madrid, Madrid, Spain
- 700 1_
- $a López-Corral, Lucía $u Hospital Universitario de Salamanca (Spain), IBSAL, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain $1 https://orcid.org/0000000319085596
- 700 1_
- $a Bramanti, Stefania $u Department of Oncology/Hematology, IRCCS Humanitas Research Hospital, via Manzoni 56, 20089 Rozzano, Milan, Italy
- 700 1_
- $a von dem Borne, Peter $u Leiden University Medical Center, Leiden, Netherlands $1 https://orcid.org/0000000274707346
- 700 1_
- $a Itälä-Remes, Maija $u Turku University Hospital, Turku, Finland
- 700 1_
- $a Martino, Massimo $u Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy $1 https://orcid.org/000000023987419X
- 700 1_
- $a Koc, Yener $u Medicana International Hospital, Istanbul, Turkey
- 700 1_
- $a Brissot, Eolia $u Sorbonne University, Department of Hematology, Saint Antoine Hospital, INSERM UMR 938, Paris, France $1 https://orcid.org/000000034471418X
- 700 1_
- $a Giebel, Sebastian $u Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland $1 https://orcid.org/0000000248274401
- 700 1_
- $a Nagler, Arnon $u Chaim Sheba Medical Center, Tel Hashomer, Israel $1 https://orcid.org/0000000207631265
- 700 1_
- $a Ciceri, Fabio $u IRCCS San Raffaele Scientific Institute, Milan, Italy $1 https://orcid.org/0000000308730123
- 700 1_
- $a Mohty, Mohamad $u Sorbonne University, Department of Hematology, Saint Antoine Hospital, INSERM UMR 938, Paris, France $1 https://orcid.org/000000027264808X $7 xx0317729
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 59, č. 10 (2024), s. 1394-1401
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38961258 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206105106 $b ABA008
- 999 __
- $a ok $b bmc $g 2263670 $s 1240067
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 59 $c 10 $d 1394-1401 $e 20240703 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20250121
